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Cutaneous Lymphoma Project Group (Burg et al. 1998) involv-
inc 827 patients CTCL. which includes MF and SS. was four
times as frequent as cutaneous B-cell (CBCL) Ixmphoma. This
indicates that in the EORTC data non-MF CL comprises about
20% of all CLs. Over 700 patients with CL have been registered
at the University of California. San Francisco CL. USA. clinic
since 1971. Approximately 5-6%- were of the non-MF type
(unpublished data). Therefore. the comparison of Iscovich et al's
(1998) data with that of Weinstock and Horm (1988) requires
qualification.
The authors note that the incidence ofCL in the USA rose from
1973 to 1984. ... and may have continued to rise (Weinstock.
1994: Koh et al. 1995). However. I could find no data or state-
ment in either of those two articles to support the suggestion of a
continued increase in the incidence ofCL since 1984. In fact. Koh
et al (1995) state. However. preliminary analyses did not find
that the crude incidence of MF continued to increase during the
subsequent 6 years (MA Weinstock. unpublished data).
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Possible relationship of the apolipoprotein E (ApoE) £4
allele to prostate cancer
Sir,
Mantzoros et al ( 1997) report that increased insulin-like growth
factor I levels are a risk factor for prostate cancer. Another molec-
ular marker. the apolipoprotein E (ApoE) E4 allele. is a risk factor
for Alzheimer's disease (Poirier et al. 1993) and might be a risk
factor for prostate cancer as well.
Alzheimer's disease and prostate cancer share a common inci-
dence pattern. Onset ofAlzheimer's disease before age 60 is infre-
quent and caused by specific gene abnormalities. Prostate cancer is
also rare in men before age 60. and there is generallv a stronc
genetic component in these cases. As men get older. the prostate
cancer incidence continues to increase. and the older cases do
not generally have a family histor- (Stephenson. 1996). Like
Alzheimer's disease. the supposition is that if men get old enough
most will develop prostate cancer.
Among the three ApoE alleles. the E4 allele confers the hirhest
Alzheimer's disease risk. The £3 allele is associated with less risk.
and the c2 allele appears to be protective. The E--E-4 genotype (i.e.
two E4 alleles) confers the highest risk of all (Strittmatter and
Roses. 1995).
The antioxidant activity ofApoE alleles protects cells in culture
from oxidative damage. The E2 allele is most protective. the E3
allele less so. and the E4 allele least protective of all (Miyata and
Smith. 1996). The decreased antioxidant activity- of E4 could
contribute to its association with Alzheimer's disease. Because
antioxidants also protect against cancer(Duthieetal. 1996).theC4
allele might predispose to the development ofmaligrnant disease.
In 35 men with prostate cancer. ApoE grenotvpe wvas determined
by polv-merase chain reaction with a standard method (Slooter et
al. 1997). The frequency of the E4 allele was 0.24. This may be
compared with a control c4 allele frequency of 0.135 or 0.138.
reported by Slooter et al (1997). The increased frequency ofthe c4
allele in the prostate cancer cases resembles its increased
frequencv in dementia of0.22 (Slooter et al. 1997).
Furthermore. the t-o prostate cancer patients who were
homozvgous £4--4 were age 52 and 58 vears. significantly
younger than the average age (67 ± 5.7 -ears. mean ± s.d.) of
the 33 other patients (P = 0.0248. Maann-Whitney U' test and
Wilcoxon rank sum It'-test corrected for ties). In Alzheimer's
disease. the patients who are homozygous £4--E4 also have the
earliest disease onset (Blacker et al. 1997). Thus. further investiga-
tion of the possible relationship of ApoE to prostate cancer. and
perhaps other forms ofcancer. might be worthwhile.
S Lehrer, 30 West 60th Street. New York-,NY 100)3. USA
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